NASDAQ$IRON
Disc Medicine Inc · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
Reported financial results for the first quarter ending March 31, 2023, and provided a business update.
Disc Medicine reported its Q1 2023 financial results, highlighting ongoing clinical studies for bitopertin and DISC-0974, in-licensing of anti-TMPRSS6 monoclonal antibodies, and a completed $62.5 million financing. The company's cash and cash equivalents were $236.4 million as of March 31, 2023, expected to fund operations into 2025.
- Continued enrollment in Phase 2 clinical studies for bitopertin (BEACON and AURORA), with topline data expected by the end of 2023.
- Ongoing Phase 1b/2 studies of DISC-0974 in patients with anemia of chronic kidney disease and myelofibrosis, with interim data expected by the end of 2023.
- In-licensed anti-TMPRSS6 monoclonal antibodies from Mabwell Therapeutics, with a Phase 1 trial expected to start in the second half of 2023.
- Completed a $62.5 million financing led by Bain Capital Life Sciences.
Headline financials
Revenue & EPS history
Disc Medicine · Revenue · Quarterly
$0
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q1 2023
-0.4%
Avg return
Earnings day
-1.7%
Avg return
5 days after
+3.9%
Avg return
30 days after
56%
10 / 18 earnings
Positive
+14.6%
Q3 2021
Best reaction
-12.4%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +1.3% | -3.8% | -10.2% | |
| Q3 2025 | -1.6% | -2.5% | +5.6% | |
| Q2 2025 | -3.4% | +0.1% | +3.0% | |
| Q1 2025 | +2.3% | +3.8% | +14.1% | |
| Q4 2024 | +0.1% | +1.6% | -3.9% | |
| Q3 2024 | -5.3% | -10.7% | -3.5% | |
| Q1 2024 | +3.5% | +8.5% | +33.3% | |
| Q4 2023 | -8.7% | -9.2% | -56.8% | |
| Q3 2023 | +1.7% | +8.1% | +27.8% | |
| Q2 2023 | +0.3% | +1.9% | -1.2% | |
| Q1 2023 | +0.6% | +1.8% | +47.6% | |
| Q4 2022 | -0.6% | +0.7% | +48.4% | |
| Q3 2022 | -0.6% | -4.7% | -2.4% | |
| Q2 2022 | -12.4% | -10.9% | -31.8% | |
| Q1 2022 | +3.6% | +10.1% | +8.6% | |
| Q4 2021 | -3.2% | -7.7% | -11.0% | |
| Q3 2021 | +14.6% | -5.6% | -12.6% | |
| Q2 2021 | +0.2% | -12.8% | +15.3% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro